Table 2.
Survival endpoints at five years of follow-up. Relapse free survival (RFS), distant metastasis free survival (DMFS) and melanoma-specific survival (MSS).
| RFS | DMFS | MSS | ||||
|---|---|---|---|---|---|---|
| Percent | 95% CI | Percent | 95% CI | Percent | 95% CI | |
| 837 patient cohort | ||||||
| None – all 837 patients | 73% | 69% – 76% | 81% | 77% – 84% | 91% | 94% – 89% |
| SLNb negative | 79% | 75% – 83% | 86% | 82% – 89% | 93% | 90% – 95% |
| SLNb positive | 52% | 43% – 60% | 64% | 55% – 72% | 85% | 78% – 90% |
| CP-GEP Low Risk | 87% | 82% – 91% | 92% | 87% – 95% | 96% | 93% – 98% |
| CP-GEP High Risk | 62% | 57% – 67% | 72% | 67% – 77% | 88% | 84% – 91% |
| SLNb negative – CP-GEP Low Risk | 89% | 83% – 93% | 94% | 89% – 96% | 96% | 94% – 99% |
| SLNb negative – CP-GEP High Risk | 70% | 63% – 76% | 78% | 71% – 83% | 89% | 84% – 93% |
| SLNb positive – CP-GEP Low Risk | 68% | 42% – 85% | 68% | 42% – 85% | 89% | 64% – 97% |
| SLNb positive – CP-GEP High Risk | 49% | 40% – 58% | 64% | 54% – 72% | 84% | 77% – 90% |
| 580 patient cohort (stage I/IIA disease only) | ||||||
| CP-GEP Low Risk | 89% | 84% – 93% | 94% | 89% – 96% | 97% | 93% – 98% |
| CP-GEP High Risk | 74% | 67% – 80% | 80% | 73% – 85% | 91% | 86% – 95% |